Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Brand name: Xevudy TM
Active ingredients: sotrovimab
What it is used for
XEVUDY has provisional approval for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require initiation of oxygen due to COVID-19 and who are at increased risk of progression to hospitalisation or death (see Section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical Trials).,The decision has been made on the basis of short term efficacy and safety data. Continued approval of this indication depends on the evidence of longer term efficacy and safety from ongoing clinical trials and post-market assessment.
How to take it
The way to take this medicine is: Intravenous Infusion.
- Store at 2 to 8 degrees Celsius
- Do not Freeze
- Protect from Light
- Shelf lifetime is 24 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
a clear, colourless or yellow to brown concentrated injection solution
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient sotrovimab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Need more information?
These trusted information partners have more on this topic.
Top results
TGA grants provisional approval to Gilead Sciences Pty Ltd to extend the use of the COVID-19 treatment, VEKLURY (remdesivir) | Therapeutic Goods Administration (TGA)
The TGA has granted provisional approval to Gilead Sciences Pty Ltd to extend the use of the COVID-19 treatment, VEKLURY (remdesivir).
Read more on TGA – Therapeutic Goods Administration website
RACGP - What is the COVID-19 treatment sotrovimab?
Reproduced with permission from The Royal Australian College of General Practitioners
Read more on RACGP - The Royal Australian College of General Practitioners website
What you need to know about COVID-19 - Immunisation Coalition
What you need to know about COVID-19 so you can protect yourself, your friends, family and the rest of the community.
Read more on Immunisation Coalition website
Top results
RACGP - What is the COVID-19 treatment sotrovimab?
Reproduced with permission from The Royal Australian College of General Practitioners
Read more on RACGP - The Royal Australian College of General Practitioners website
